Skip to content
lifestyle.easyhouseremodeling.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Electra Therapeutics
Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering
September 17, 2026
Electra Therapeutics Announces Initiation of a Phase 1 Trial of ELA822, a Novel SIRPγ-Specific Antibody Designed to Treat T Cell-Mediated Immune and Inflammatory Diseases
September 10, 2026
Electra Therapeutics Appoints Chris Clark, CFA, to Chief Financial Officer
September 9, 2026
Electra Therapeutics Announces First Patient Dosed in Phase 1 Study of Ipsoprubart (ELA026) in T Cell Malignancies
May 5, 2026